Vivimed Labs' board approved Q2/H1 consolidated results with a reported loss.

Auditors issued a qualified opinion due to unrecorded interest of ₹30.71 Cr for H1, pushing the total loss to ₹43.51 Cr.

Board also approved a pre-packaged insolvency process (shareholder approval pending) and expects trading suspension revocation.